- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03335631
Preference-Based Exercise RCT for Men With PC on ADT (PBExRCT)
A Preference-Based Trial of Two Exercise Delivery Methods in Men With PC on ADT
Prostate cancer affects 1 in 7 men. Half of these men are treated with androgen deprivation therapy (ADT). ADT slows disease progression and prolongs survival, but it also leads to worse quality of life (QOL), fatigue, loss of strength and fitness, osteoporosis, and diabetes.
The investigators' recent research has shown that individually supervised exercise, supervised group exercise and home-based exercise are equally good at improving these side effects. Now the investigators are doing a larger trial with multiple centres to see whether supervised group or home-based exercise is clinically better and more economical.
A major challenge in such trials is that a significant number of men refuse to be randomized because (a) the participant lives too far from a study centre and cannot come for supervised exercise; or (b) the participant has a strong preference as to which type of exercise program the participant wants to do. Experts have raised concerns that classic randomized trials are too restrictive, selective, and less practical; the study results are less applicable to the real world. Despite its obvious importance, it is not known whether men who refuse to be randomized to an exercise trial but are otherwise willing to participate would benefit similarly to men who are randomized. In this study, we will recruit men who are otherwise eligible for our randomized trial but refuse it for one of the reasons above. We will allow these men to choose either supervised group or home-based exercise, and then compare them to the men who are being randomized to the two treatments in 3 important ways. First, are participants similar in terms of personal characteristics, QOL, and fitness levels? Second, do participants respond similarly to exercise in terms of QOL and physical fitness benefits? Third, do participants actually exercise as much as the randomized men? This work will help the research team understand whether there is a need to change the way exercise trials are done in order to be more relevant and wide-reaching for Canadians with a variety of health conditions.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
BACKGROUND: The backbone of scientific evidence to address most scientific questions, including behavioural interventions, is randomized controlled trials (RCTs). Prostate cancer is the most common malignancy in men, affecting 1 in 7 men. Almost 50% of these men will receive androgen deprivation therapy (ADT) at some point after diagnosis to reduce disease progression and prolong survival. ADT is associated with multiple adverse effects, including diminished quality of life (QOL), fatigue, reduced muscle mass, and metabolic effects. Numerous RCTs in the setting of men on ADT have demonstrated that exercise programs, particularly supervised 1:1 in-centre programs, are clinically effective. However, they are resource-intensive and have low scalability. Alternative delivery models such as group-based supervised exercise or home-based exercise are promising alternatives but require rigorous efficacy data. While conducting a two-centre exercise trial comparing different exercise delivery models, fewer than 40% of eligible men agreed to participate. Two common reasons why men declined participation were distance to exercise centres and unwillingness to be randomized. Novel clinical trial designs, such as preference-based trials, may help answer effectiveness questions and enhance generalizability by recruiting a more representative pool of men. Increased efficiencies in recruitment, however, may come at a cost of bias with non-randomized designs as well as differential effects of exercise and varying adherence. In parallel with a multi-centre phase III RCT funded by CIHR, we propose to conduct a pilot preference-based trial, examining 3 key issues. First, can we successfully enroll men who are unwilling to be randomized due either to distance from centre or a strong preference for one exercise delivery model? Second, are these men different from men who are randomized in terms of baseline characteristics, study retention, and adherence to the intervention? Third, are the benefits of an exercise program similar to men who are randomized to the same arm?
OBJECTIVES:
To determine, in men with PC on ADT who are otherwise eligible to participate in a RCT of different exercise delivery models but decline to be randomized due to distance from the study centre or strong preference for one exercise delivery model:
- What proportion of these men is willing to be enrolled in a preference-based trial.
- How comparable are baseline characteristics of men who agree to participate in the intervention arm of their choice and all those in the randomized study?
- How comparable are study retention and adherence to the intervention for men in the corresponding arms of the preference based trial and randomized trial?
- How comparable are the benefits in terms of quality of life (QOL) and physical fitness outcomes in those with a preference for a particular exercise and those without a preference?
HYPOTHESES
- Systematic differences exist in baseline characteristics, specifically distance to the study centre, age, education, prior experience with participating in exercise programs, and fatigue severity among participants willing to be randomized versus not randomized to an exercise intervention.
- Adherence will be greater among those selecting treatment by preference vs being randomized.
- Benefits (QOL and fitness) will be greater among those selecting treatment versus being randomized.
METHODS: Patients aged 18 or older on ADT for high-risk/locally advanced, biochemically relapsed, or asymptomatic metastatic prostate cancer will be eligible if they are otherwise eligible for an ongoing phase III RCT of exercise but decline to participate due to either distance from study centre or strong preference for one exercise delivery model. The main phase III RCT is examining a 6-month individualized, progressive, mixed-modality exercise program including aerobic, resistance, and flexibility components delivered using one of two delivery models: supervised in-centre group exercise 3 times weekly or home-based exercise supported by a Fitbit, smart phone app, and remote health coach.
To meet the objectives of this pilot preference trial, we will enroll 50 men per preference arm at three experienced study sites (Princess Margaret Cancer Centre, Toronto, Scarborough and Rouge Hospital, Scarborough and the University of Calgary, Calgary and). Aim 1. We will report the proportion of men who are eligible for the preference-based trial who agree to participate, overall and by treatment arm and reason for refusal to be randomized.
Aim 2/Hypotheses 1 and 2. We will compare the participants in the preference-based trial to those in the RCT. Comparisons of baseline characteristics will be between the total number of participants in the RCT compared separately to each arm of the preference trial. ANOVA will be used for continuous variables and chi-square analysis for categorical variables. Variables to be compared include distance from participants' home to the study centre, age, education, prior participation in an exercise program, and symptom severity. Differences will be presented with 95% CIs.
Aim 3/Hypothesis 3. Within-group change scores will be assessed for the preference-based groups, and the mean changes along with the 95%CIs will be reported. Next, we will compare these changes for the co-primary and secondary outcomes between the preference-based groups and the phase III RCT (e.g., combined preference arms to combined RCT arm) to obtain the so-called selection-effect. Finally, although it is subject to confounding by unknown preference effects in the RCT participants, we will estimate the differences between outcomes in those randomized to and choosing each specific exercise delivery method, using constrained linear mixed effects model adjusting for the baseline value and ADT duration. Skewed data will be transformed as appropriate.
SIGNIFICANCE: Behavioural interventions require significant patient commitment and although most RCTs to date have shown evidence of benefit on various outcomes, recruitment rates have been low and many otherwise eligible men are not willing to be randomized for different reasons. Designing trials that allow inclusion of such men is obviously going to improve generalizability but whether the results of interventions are similarly effective and understanding the feasibility and potential biases of enrolling such men are fundamental unresolved issues. This pilot study will take advantage of an existing trial to begin to answer these questions and determine whether a larger preference-based trial is worth undertaking. Our findings have potential widespread implications for behavioural trials across many health care settings.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Alberta
-
Calgary, Alberta, Kanada
- University of Calgary/Tom Baker Cancer Centre
-
-
Ontario
-
Scarborough, Ontario, Kanada, M1P 2T7
- Scarborough and Rouge Hospital
-
Toronto, Ontario, Kanada, M5G 2C4
- University Health Network
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- men with histologically confirmed PC who are starting or continuing on ADT for at least 6 months
- fluent in English,
- able to provide consent.
Exclusion Criteria:
- already meeting guidelines for moderate to vigorous physical activity (MVPA)
- conditions that would interfere with ability to participate
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Group-supervised
This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist.
Supervised sessions will be delivered in a group format with 4-8 participants per group.
Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session.
Aerobic training will involve 30 minutes of low-impact step aerobics.
Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups.
Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
|
Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
|
|
Kokeellinen: Home-based
The same protocol and training frequency as the supervised programs described above will be followed.
However, all exercises will be completed independently by participants.
Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group).
Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase.
This will help to ensure participant adherence, appropriate progression, and safety.
|
Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Functional Assessment of Cancer Therapy-Fatigue (FACT-F) scale over time
Aikaikkuna: Baseline, 3, 6, 12 months
|
The FACT-F is a questionnaire that includes 13 items measuring cancer-related fatigue. Total Score Range = 0-52 (higher score = lower fatigue) |
Baseline, 3, 6, 12 months
|
|
Change in 6 minute walk test (6MWT) scores over time
Aikaikkuna: Baseline, 3, 6, 12 months
|
The 6MWT is a commonly used, validated measure that assesses functional endurance.
|
Baseline, 3, 6, 12 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Functional Assessment of Cancer Therapy-General (FACT-G) scale over time
Aikaikkuna: Baseline, 3, 6, 12 months
|
The FACT-G is a questionnaire that is well-validated and widely used to measure quality of life (QOL). Total Score Range = 0-108 (higher score = higher QOL) |
Baseline, 3, 6, 12 months
|
|
Change in Functional Assessment of Cancer Therapy-Prostate (FACT-P) scale over time
Aikaikkuna: Baseline, 3, 6, 12 months
|
The FACT-P is a questionnaire that supplements the FACT-G with 12 prostate-specific items covering domains of urinary function, sexual function, pain, and related symptoms. Range = 0-48 (higher score = fewer prostate-specific symptoms) |
Baseline, 3, 6, 12 months
|
|
Change in 5 Timed Chair Stand Test over time
Aikaikkuna: Baseline, 3, 6, 12 months
|
A common, simple, and validated measure of functional lower body strength.
|
Baseline, 3, 6, 12 months
|
|
Change in grip strength using a Jamar dynamometer over time
Aikaikkuna: Baseline, 3, 6, 12 months
|
Grip strength is a measure of upper body strength and predicts long-term disability and mortality in middle-aged and older adults.
|
Baseline, 3, 6, 12 months
|
|
Change in body composition (fat mass, fat free mass, and body fat percentage) measured via body impedance analysis (BIA) over time
Aikaikkuna: Baseline, 6, 12 months
|
Body composition will be measured using bioelectrical impedance analysis (BIA).
|
Baseline, 6, 12 months
|
|
Change in fasting lipids over time
Aikaikkuna: Baseline, 6, 12 months
|
Fasting lipids will be measured.
|
Baseline, 6, 12 months
|
|
Change in blood glucose over time
Aikaikkuna: Baseline, 6, 12 months
|
Blood glucose will be measured.
|
Baseline, 6, 12 months
|
|
Change in glycated hemoglobin over time
Aikaikkuna: Baseline, 6, 12 months
|
Glycated hemoglobin will be measured.
|
Baseline, 6, 12 months
|
|
Change in hemoglobin over time
Aikaikkuna: Baseline, 6, 12 months
|
Hemoglobin will be measured.
|
Baseline, 6, 12 months
|
|
Change in prostate specific antigen (PSA) over time
Aikaikkuna: Baseline, 6, 12 months
|
Prostate-specific antigen (PSA) will be measured.
|
Baseline, 6, 12 months
|
|
Change in weekly minutes of moderate-vigorous physical activity (MVPA) over time
Aikaikkuna: Baseline, 3, 6, 12 months
|
Accelerometry will be used to measure weekly minutes of MVPA as an indicator of adherence at each time point.
|
Baseline, 3, 6, 12 months
|
|
Change in Health Care Climate Questionnaire (HCCQ) over time
Aikaikkuna: Baseline only
|
The Health Care Climate Questionnaire (HCCQ short form) assess participant perceptions of their health care team. Range = 0-7 (higher = better) |
Baseline only
|
|
Change in Behavioral Regulations in Exercise Questionnaire-2 (BREQ-2) over time
Aikaikkuna: Baseline, 6, 12 months
|
Behavioral Regulations in Exercise Questionnaire-2 (BREQ-2) is a validated questionnaire that assess predictors of adherence. Comprised of 4 subscales: External regulation, range = 0-4 (higher = better) Introjected regulation, range = 0-4 (higher = better) Identified regulation, range = 0-4 (higher = better) Intrinsic regulation, range = 0-4 (higher = better) |
Baseline, 6, 12 months
|
|
Change in Psychological Need Support and Frustration Scale - Relatedness Items (PNSF - Relatedness Items) over time
Aikaikkuna: Baseline, 6, 12 months
|
The Psychological Need Support and Frustration Scale - Relatedness Items will be used to measure relatedness. Total Score Range = 1-5 (higher = better) |
Baseline, 6, 12 months
|
|
Change in Planning, Attitudes, & Barriers scale over time
Aikaikkuna: Baseline, 6, 12 months
|
The Planning, Attitudes, & Barriers (PAB) scale is a validated questionnaire that will be used to assess the likelihood of exercise behavior and adherence over time. Comprised of 11 subscales: Attitudes subscale, range = 1-7 (higher = better); Support subscale, range = 1-7 (higher = better); Motivation subscale, range = 1-7 (higher = better); Intentions subscale, range = 1-7 (higher = better); Planning subscale, range = 1-7 (higher = better); Disease/treatment influences subscale, range = 1-7 (higher = better); Disease/treatment frequency subscale, range = 1-7 (higher = better); Life-related influences subscale, range = 1-7 (higher = better); Life-related frequency subscale, range = 1-7 (higher = better); Motivated-related influences subscale, range = 1-7 (higher = better); Motivated-related frequency subscale, range = 1-7 (higher = better) Note: No total score is derived from this questionnaire |
Baseline, 6, 12 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Shabbir MH Alibhai, MD, MSc, University Health Network, Toronto
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 17-5506
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Eturauhassyöpä
-
National Cancer Institute (NCI)RekrytointiStage III Sinonasal Cancer AJCC v8 | Stage IVA Sinonasal Cancer AJCC v8 | Vaihe IVB Sinonasal Cancer AJCC v8 | Sinonasaalinen okasolusyöpäYhdysvallat
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ValmisLymfaödeema | Perioperatiiviset/postoperatiiviset komplikaatiot | Vaiheen II Vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer AJCC v7 | Vaihe IA Vulvar Cancer AJCC v7 | Vaihe IB Vulvar Cancer AJCC v7 | Vaihe...Yhdysvallat
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiVaiheen III vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Epäsuoran levyepiteelisyöpä | Stage IVA Vulvar Cancer AJCC v7Yhdysvallat
-
Samsung Medical CenterValmisHER2-positiivinen Refractory Advanced CancerKorean tasavalta
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiVaiheen II Vulvar Cancer AJCC v8 | Vaiheen IIIC vulvar Cancer AJCC v8 | Stage IVA Vulvar Cancer AJCC v8 | Kolmannen vaiheen ulkosynnyttäjäsyöpä AJCC v8 | Vaihe IIIA Vulvar Cancer AJCC v8 | Vaihe IIIB Vulvar Cancer AJCC v8Yhdysvallat
-
Everest Medicines (Beijing) Co., Ltd.Ei vielä rekrytointiaSquamous Non-Small Cell Lung Cancer sqNSCLC
-
First Affiliated Hospital of Zhejiang UniversityYiwu Central HospitalEi vielä rekrytointiaMahalaukun adenokarsinooma | Esophagogastric Juction Cancer | Asiantunteva yhteensopivuusvirheiden korjausKiina
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAktiivinen, ei rekrytointiHaiman adenokarsinooma | Stage III haimasyöpä American Joint Committee on Cancer v8 | T0-tasainen haimasyöpä American Joint Committee on Cancer v8 | Vaiheen I haimasyöpä American Joint Committee on Cancer v8 | Vaiheen IV haimasyöpä American Joint Committee on Cancer v8Yhdysvallat
-
University of UtahNational Cancer Institute (NCI)ValmisVäsymys | Istuva elämäntapa | Metastaattinen eturauhassyöpä | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8 | Stage IVB Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8Yhdysvallat
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...ValmisTutki kiinalaisia naisia, jotka eivät ole noudattaneet American Cancer Societyn mammografiaseulontaohjeitaYhdysvallat